Terry Chrisomalis

505 posts

Terry Chrisomalis

Terry Chrisomalis

@BioAnalysisCent

Founder of "Biotech Analysis Central" marketplace at Seeking Alpha, Biotech author at Seeking Alpha Journalist of Biotech, Follow me on Stocktwits BiopharmaPro

Joined Mayıs 2018
2K Following725 Followers
Terry Chrisomalis retweeted
Patent Pundit
Patent Pundit@PunditPatent·
$ABUS - The Patent Office issued ABUS it's newest patent this morning. IMO, the new patent covers both the $MRNA and $PFE / $BNTX vaccines. It has an effective filing date (for prior art) dating back to 2009.
Patent Pundit tweet media
Patent Pundit@PunditPatent

In addition to covering the $MRNA Covid Vaccine, it looks like the new patent application that $ABUS got allowed on August 30, 2021 (app. no. 17/227802) also covers the Pfizer-BioNTech Covid Vaccine.

English
5
25
93
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
$ABUS Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection biospace.com/article/releas…
English
0
0
1
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
$ABUS "Arbutus Announces New Data On Ab-729 And Ab-836 Programs With Presentation Of Five Abstracts At The Easl International Liver Congress™ 2021 - All Selected For Best Of Ilc™" globenewswire.com/news-release/2…
English
0
0
1
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
$EPZM "Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge" #comment-89292337" target="_blank" rel="nofollow noopener">seekingalpha.com/article/443608…
English
0
0
0
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
@RNAiAnalyst $ABUS Recent HBV data, but more importantly another catalyst. They still releasing AB-729 60 mg multi-dose every 8-weeks dose. If they can prove up to every 8 weeks or every 12-weeks that would be huge for Hep B treatment. This is coming any day now Q4 2020.
English
0
0
8
0
Dirk Haussecker
Dirk Haussecker@RNAiAnalyst·
$ABUS why the strength today?
English
5
0
5
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
$ABUS $DRNA $VIR $ALNY $ARWR $JNJ
Dirk Haussecker@RNAiAnalyst

#HBV RNAi...AASLD updates provided 1st snapshots of single shot knockdown for $ABUS competition. Here, $DRNA's/Roche's RG6346 comes up short in kd duration: $VIR $ALNY $ARWR $JNJ

QCT
1
2
3
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
@biot_notes @MedResCol Read the data The final 16 weeks multi-dose did not reach plateau. 3 patients still getting -1.73 and still declining. That is only 16 weeks. You can't compare the other companies which have observed 24 weeks or 48 weeks. That fast of a decline in HBV in that short of a time good
English
0
0
1
0
.
.@biot_notes·
@MedResCol 1-1.5 log reduction seems a bit weak, doesn't it? What gives you confidence relative to some of the other drugs in development?
English
1
0
1
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
$ABUS Impressed that the 60 mg AB-729 multi-dose (once every 4 weeks) hasn't reached a plateau past 16 weeks. Mean reduction of -1.44 log IU/ML at week 16 in Hepatitis B patients, no plateau yet past week 16.
English
0
0
3
0
Terry Chrisomalis
Terry Chrisomalis@BioAnalysisCent·
$ABUS Going to present at AASLD On Sunday November 15, 2020 , with press release afterwards on results. Monday November 16th conference call to discuss data. First look at 60 mg AB-729 multi-dose cohort, plus long-term single dose cohorts of 60 mg and 90 mg of AB-729 for Hep B
English
0
2
4
0
Terry Chrisomalis retweeted
Dirk Haussecker
Dirk Haussecker@RNAiAnalyst·
$ABUS tempted to buy here on weakness ahead of HBV RNAi multi-dose presentation at AASLD; but then again: if data good, they'll sell more shares.
English
5
1
12
0

Discover

@RNAiAnalyst @biot_notes @elonmusk @BarackObama @taylorswift13 @cristiano @BillGates @NASA